Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 38, Issue 1, 2012, Pages 36-50

  El Khoury, Marie Anne ^a,b,c   Gorgievski, Victor ^a,b,c   Moutsimilli, Larissa ^a,b,c   Giros, Bruno ^a,b,c,d   Tzavara, Eleni T ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CNRS   (France)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Attentional set shifting; Cognition; Dopamine transporter knock out mice; Metabotropic glutamate receptors; Psychosis; TRPV1

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; DOPAMINE; ENDOCANNABINOID; GLUTAMIC ACID; METABOTROPIC RECEPTOR; NALOXONE; PSYCHOSTIMULANT AGENT; RIMONABANT; VANILLOID RECEPTOR 1;

BASAL GANGLION; BRAIN FUNCTION; COCAINE DEPENDENCE; COGNITION; COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; HUNTINGTON CHOREA; HYPERACTIVITY; MENTAL DISEASE; MOTOR CONTROL; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; OPIATE ADDICTION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN INTERACTION; PSYCHOMOTOR ACTIVITY; PSYCHOSIS; RECEPTOR UPREGULATION; REVIEW; REWARD; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT INDICATION;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; ENDOCANNABINOIDS; MENTAL DISORDERS; NERVE NET; NEURONS;

EID: 84862838626     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.12.005     Document Type: Review

References (195)

1. Aceto M.D., Scates S.M., Lowe J.A., Martin B.R. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996, 278:1290-1295.
2. Acquas E., Pisanu A., Marrocu P., Goldberg S.R., Di Chiara G. Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur J Pharmacol 2001, 419:155-161.
3. Ali A.B. Presynaptic cell dependent modulation of inhibition in cortical regions. Curr Neuropharmacol 2009, 7:125-131.
4. Alonso R., Voutsinos B., Fournier M., Labie C., Steinberg R., Souilhac J., et al. Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 1999, 91:607-620.
5. Andre V.M., Cepeda C., Cummings D.M., Jocoy E.L., Fisher Y.E., William Yang X., et al. Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. Eur J Neurosci 2010, 31:14-28.
6. Auclair N., Otani S., Soubrie P., Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 2000, 83:3287-3293.
7. Baker D.A., Xi Z.X., Shen H., Swanson C.J., Kalivas P.W. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002, 22:9134-9141.
8. Bales K.R., Tzavara E.T., Wu S., Wade M.R., Bymaster F.P., Paul S.M., et al. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J Clin Invest 2006, 116:825-832.
9. Balschun D., Wetzel W. Inhibition of mGluR5 blocks hippocampal LTP in vivo and spatial learning in rats. Pharmacol Biochem Behav 2002, 73:375-380.
10. Balschun D., Zuschratter W., Wetzel W. Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience 2006, 142:691-702.
11. Bari M., Bonifacino T., Milanese M., Spagnuolo P., Zappettini S., Battista N., et al. The endocannabinoid system in rat gliosomes and its role in the modulation of glutamate release. Cell Mol Life Sci 2011, 68:833-845.
12. Beltramo M., de Fonseca F.R., Navarro M., Calignano A., Gorriti M.A., Grammatikopoulos G., et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci 2000, 20:3401-3407.
13. Bennion D., Jensen T., Walther C., Hamblin J., Wallmann A., Couch J., et al. Transient receptor potential vanilloid 1 agonists modulate hippocampal CA1 LTP via the GABAergic system. Neuropharmacology 2011, 61:730-738.
14. Bequet F., Uzabiaga F., Desbazeille M., Ludwiczak P., Maftouh M., Picard C., et al. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus. Eur J Neurosci 2007, 26:3458-3464.
15. Berendse H.W., Groenewegen H.J. Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum. J Comp Neurol 1990, 299:187-228.
16. Birrell J.M., Brown V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 2000, 20:4320-4324.
17. Buczynski M.W., Parsons L.H. Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol 2010, 160:423-442.
18. Bymaster F.P., Felder C., Ahmed S., McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 2002, 1:163-181.
19. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007, 30:211-219.
20. Carlsson G., Wang Y., Alger B.E. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci 2002, 5:723-724.
21. Centonze D., Battista N., Rossi S., Mercuri N.B., Finazzi-Agro A., Bernardi G., et al. A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic transmission. Neuropsychopharmacology 2004, 29:1488-1497.
22. Chaperon F., Thiebot M.H. Behavioral effects of cannabinoid agonists in animals. Crit Rev Neurobiol 1999, 13:243-281.
23. Chavez A.E., Chiu C.Q., Castillo P.E. TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci 2010, 13:1511-1518.
24. Chen J., Paredes W., Lowinson J.H., Gardner E.L. Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 1990, 190:259-262.
25. Chevaleyre V., Castillo P.E. Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron 2004, 43:871-881.
26. Chiu C.Q., Puente N., Grandes P., Castillo P.E. Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J Neurosci 2010, 7236-7248.
27. Colombo G., Serra S., Vacca G., Carai M.A., Gessa G.L. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol Biochem Behav 2005, 81:369-380.
28. Cools R. Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist 2008, 14:381-395.
29. Corbille A.G., Valjent E., Marsicano G., Ledent C., Lutz B., Herve D., et al. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci 2007, 27:6937-6947.
30. Darrah J.M., Stefani M.R., Moghaddam B. Interaction of N-methyl-d-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav Pharmacol 2008, 19:225-234.
31. Day J.C., Fibiger H.C. Dopaminergic regulation of septohippocampal cholinergic neurons. J Neurochem 1994, 63:2086-2092.
32. De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2003, 2:5.
33. De Vries T.J., Schoffelmeer A.N. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 2005, 26:420-426.
34. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001, 7:1151-1154.
35. Del Arco A., Mora F. Prefrontal cortex-nucleus accumbens interaction: in vivo modulation by dopamine and glutamate in the prefrontal cortex. Pharmacol Biochem Behav 2008, 90:226-235.
36. Del Arco A., Mora F. Neurotransmitters and prefrontal cortex-limbic system interactions: implications for plasticity and psychiatric disorders. J Neural Transm 2009, 116:941-952.
37. Deutch A.Y., Lee M.C., Gillham M.H., Cameron D.A., Goldstein M., Iadarola M.J. Stress selectively increases fos protein in dopamine neurons innervating the prefrontal cortex. Cereb Cortex 1991, 1:273-292.
38. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 1999, 375:13-30.
39. Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3:771-784.
40. Diana M., Melis M., Gessa G.L. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 1998, 10:2825-2830.
41. Diana M., Melis M., Muntoni A.L., Gessa G.L. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci U S A 1998, 95:10269-10273.
42. Doherty J., Dingledine R. Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr Opin Pharmacol 2003, 3:46-53.
43. Doig N.M., Moss J., Bolam J.P. Cortical and thalamic innervation of direct and indirect pathway medium-sized spiny neurons in mouse striatum. J Neurosci 2010, 30:14610-14618.
44. Dong Y., Nasif F.J., Tsui J.J., Ju W.Y., Cooper D.C., Hu X.T., et al. Cocaine-induced plasticity of intrinsic membrane properties in prefrontal cortex pyramidal neurons: adaptations in potassium currents. J Neurosci 2005, 25:936-940.
45. Egerton A., Brett R.R., Pratt J.A. Acute delta9-tetrahydrocannabinol-induced deficits in reversal learning: neural correlates of affective inflexibility. Neuropsychopharmacology 2005, 30:1895-1905.
46. Egerton A., Allison C., Brett R.R., Pratt J.A. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev 2006, 30:680-695.
47. Fadda P., Scherma M., Spano M.S., Salis P., Melis V., Fattore L., et al. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 2006, 17:1629-1632.
48. Fernandez-Ruiz J., Lastres-Becker I., Cabranes A., Gonzalez S., Ramos J.A. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 2002, 66:257-267.
49. Fernández-Ruiz J., Hernández M., Ramos J.A. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010, 16:e72-e91.
50. Ferraro L., Tomasini M.C., Gessa G.L., Bebe B.W., Tanganelli S., Antonelli T. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb Cortex 2001, 11:728-733.
51. Fitch T.E., Sahr R.N., Eastwood B.J., Zhou F.C., Yang C.R. Dopamine D1/5 receptor modulation of firing rate and bidirectional theta burst firing in medial septal/vertical limb of diagonal band neurons in vivo. J Neurophysiol 2006, 95:2808-2820.
52. Fortin D.A., Levine E.S. Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons. Cereb Cortex 2007, 17:163-174.
53. Fourgeaud L., Mato S., Bouchet D., Hémar A., Worley P.F., Manzoni O.J. A single in vivo exposure to cocaine abolishes endocannabinoid-mediated long-term depression in the nucleus accumbens. J Neurosci 2004, 24:6939-6945.
54. Fowler C.J., Jacobsson S.O. Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide-targets for drug development?. Prostaglandins Leukot Essent Fatty Acids 2002, 66:193-200.
55. Fremeau R.T., Kam K., Qureshi T., Johnson J., Copenhagen D.R., Storm-Mathisen J., et al. Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites. Science 2004, 304:1815-1819.
56. French E.D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997, 8:649-652.
57. Gainetdinov R.R., Sotnikova T.D., Caron M.G. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci 2002, 23:367-373.
58. Galarreta M., Erdelyi F., Szabo G., Hestrin S. Cannabinoid sensitivity and synaptic properties of 2 GABAergic networks in the neocortex. Cereb Cortex 2008, 18:2296-2305.
59. Garcia-Garcia A.L., Elizalde N., Matrov D., Harro J., Wojcik S.M., Venzala E., et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol Psychiatry 2009, 66:275-282.
60. Gardner E.L. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 2005, 81:263-284.
61. Gerdeman G.L. Endocannabinoids at the synapse: retrograde signaling and presynaptic plasticity in the brain. Cannabinoids and the brain 2008, Springer Verlag. A. Kofalvi (Ed.).
62. Gerdeman G.L., Fernandez-Ruiz J. The endocannabinoid system in the physiology and pathology in the basal ganglia. Cannabinoids and the brain 2008, Springer Verlag. A. Kofalvi (Ed.).
63. Gerdeman G., Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001, 85:468-471.
64. Gerdeman G.L., Ronesi J., Lovinger D.M. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 2002, 5:446-451.
65. Gessa G.L., Casu M.A., Carta G., Mascia M.S. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur J Pharmacol 1998, 355:119-124.
66. Gibson H.E., Edwards J.G., Page R.S., Van Hook M.J., Kauer J.A. TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 2008, 57:746-759.
67. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
68. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999, 2:358-363.
69. Giuffrida A., Beltramo M., Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001, 298:7-14.
70. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29:2108-2114.
71. Goldberg T.E., Weinberger D.R. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J Clin Psychiatry 1996, 57(Suppl 9):62-65.
72. Goldstein R.Z., Volkow N.D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002, 159:1642-1652.
73. Goto Y., Grace A.A. Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci 2005, 8:805-812.
74. Goto Y., Otani S., Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 2007, 53:583-587.
75. Goutopoulos A., Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther 2002, 95:103-117.
76. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
77. Grueter B.A., Brasnjo G., Malenka R.C. Postsynaptic TRPV1 triggers cell type-specific long-term depression in the nucleus accumbens. Nat Neurosci 2010, 13:1519-1525.
78. Hajos N., Freund T.F. Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 2002, 121:73-82.
79. Hajos N., Freund T.F. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 2002, 43:503-510.
80. Hampson R.E., Deadwyler S.A. Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. J Neurosci 2000, 20:8932-8942.
81. Hao S., Avraham Y., Mechoulam R., Berry E.M. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000, 392(3):147-156. Mar 31.
82. Haring M., Kaiser N., Monory K., Lutz B. Circuit specific functions of cannabinoid CB1 receptor in the balance of investigatory drive and exploration. PLoS One 2011, 6:e26617.
83. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 2002, 87:1932-1936.
84. Hermann H., Marsicano G., Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002, 109:451-460.
85. Hersi A.I., Rowe W., Gaudreau P., Quirion R. Dopamine D1 receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory-impaired aged rats. Neuroscience 1995, 69:1067-1074.
86. Hester R., Nestor L., Garavan H. Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users. Neuropsychopharmacology 2009, 34:2450-2458.
87. Hildebrand B.E., Nomikos G.G., Hertel P., Schilstrom B., Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 1998, 779:214-225.
88. Hill E.L., Gallopin T., Ferezou I., Cauli B., Rossier J., Schweitzer P., et al. Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol 2007, 97:2580-2589.
89. Hutcheson D.M., Tzavara E.T., Smadja C., Valjent E., Roques B.P., Hanoune J., et al. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 2000, 125:1567-1577.
90. Jaber M., Robinson S.W., Missale C., Caron M.G. Dopamine receptors and brain function. Neuropharmacology 1996, 35:1503-1519.
91. Jacob W., Yassouridis A., Marsicano G., Monory K., Lutz B., Wotjak C.T. Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 2009, 7:685-698.
92. Katona I., Sperlagh B., Magloczky Z., Santha E., Kofalvi A., Czirjak S., et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000, 100:797-804.
93. Kofalvi A., Rodrigues R.J., Ledent C., Mackie K., Vizi E.S., Cunha R.A., et al. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 2005, 25:2874-2884.
94. Lafourcade M., Elezgarai I., Mato S., Bakiri Y., Grandes P., Manzoni O.J. Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One 2007, 2:e709.
95. Lane S.D., Cherek D.R., Pietras C.J., Steinberg J.L. Performance of heavy marijuana-smoking adolescents on a laboratory measure of motivation. Addict Behav 2005, 30:815-828.
96. Le Foll B., Goldberg S.R. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005, 312:875-883.
97. Lichtman A.H., Dimen K.R., Martin B.R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 1995, 119:282-290.
98. Lichtman A.H., Varvel S.A., Martin B.R. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 2002, 66:269-285.
99. Long L.E., Malone D.T., Taylor D.A. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 2006, 31:795-803.
100. Lu X.Y., Churchill L., Kalivas P.W. Expression of D1 receptor mRNA in projections from the forebrain to the ventral tegmental area. Synapse 1997, 25:205-214.
101. Lu X.R., Ong W.Y., Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in monkey basal forebrain. J Neurocytol 1999, 28:1045-1051.
102. Lupica C.R., Riegel A.C., Hoffman A.F. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 2004, 143:227-234.
103. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008, 11:152-159.
104. Maldonado R., de Fonseca Rodríguez F. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 2002, 22:3326-3331.
105. Maldonado R., Blendy J.A., Tzavara E., Gass P., Roques B.P., Hanoune J., et al. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science 1996, 273:657-659.
106. Maldonado R., Valverde O., Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006, 29:225-232.
107. Malone D.T., Taylor D.A. Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br J Pharmacol 1999, 128:21-26.
108. Margulies J.E., Hammer R.P. D9-tetrahydrocannabinol alterscerebral metabolism in a biphasic, dose-dependent manner in rat brain. Eur J Pharmacol 1991, 202:373-378.
109. Marinelli S., Di Marzo V., Berretta N., Matias I., Maccarrone M., Bernardi G., et al. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci 2003, 23:3136-3144.
110. Marinelli S., Di Marzo V., Florenzano F., Fezza F., Viscomi M.T., van der Stelt M., et al. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 2007, 32:298-308.
111. Marsicano G., Kuner R. Anatomical distribution of receptors, ligands and enzymes in the brain and the spinal cord; circuitries and neurochemistry. Cannabinoids and the brain 2008, Springer Verlag. A. Kofalvi (Ed.).
112. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999, 11:4213-4224.
113. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
114. Martin R.S., Secchi R.L., Sung E., Lemaire M., Bonhaus D.W., Hedley L.R., et al. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl) 2003, 165:128-135.
115. Martin-Santos R., Fagundo A.B., Crippa J.A., Atakan Z., Bhattacharyya S., Allen P., et al. Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 2010, 40:383-398.
116. Mas-Nieto M., Pommier B., Tzavara E.T., Caneparo A., Da Nascimento S., Le Fur G., et al. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 2001, 132:1809-1816.
117. Masserano J.M., Karoum F., Wyatt R.J. SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav Pharmacol 1999, 10:429-432.
118. Mato S., Robbe D., Puente N., Grandes P., Manzoni O.J. Presynaptic homeostatic plasticity rescues long-term depression after chronic Delta 9-tetrahydrocannabinol exposure. J Neurosci 2005, 25:11619-11627.
119. Melis M., Perra S., Muntoni A.L., Pillolla G., Lutz B., Marsicano G., et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 2004, 24:10707-10715.
120. Meltzer H.Y., Arvanitis L., Bauer D., Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004, 161:975-984. Meta-Trial Study Group.
121. Mendez P., Bacci A. Assortment of GABAergic plasticity in the cortical interneuron melting pot. Neural Plast 2011, 2011:976856.
122. Mezey E., Toth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A 2000, 97:3655-3660.
123. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009, 34:593-606.
124. Miller A.S., Walker J.M. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur J Pharmacol 1995, 279:179-185.
125. Monory K., Blaudzun H., Massa F., Kaiser N., Lemberger T., Schütz G., et al. Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol 2007, 5:e269.
126. Morice E., Billard J.M., Denis C., Mathieu F., Betancur C., Epelbaum J., et al. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology 2007, 32:2108-2116.
127. Moss J., Bolam J.P. A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals. J Neurosci 2008, 28:11221-11230.
128. Moutsimilli L., Farley S., Dumas S., El Mestikawy S., Giros B., Tzavara E.T. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 2005, 49:890-900.
129. Moutsimilli L., Farley S., El Khoury M.A., Chamot C., Sibarita J.B., Racine V., et al. Antipsychotics increase vesicular glutamate transporter 2 (VGLUT2) expression in thalamolimbic pathways. Neuropharmacology 2008, 54:497-508.
130. Musella A., De Chiara V., Rossi S., Prosperetti C., Bernardi G., Maccarrone M., et al. TRPV1 channels facilitate glutamate transmission in the striatum. Mol Cell Neurosci 2009, 40:89-97.
131. Nava F., Carta G., Battesi A.M., Gessa G.L. D2 dopamine receptors enable D-9-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. Br J Pharmacol 2000, 130:1201-1210.
132. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002, 67:53-83.
133. Ohno-Shosaku T., Shosaku J., Tsubokawa H., Kano M. Cooperative endocannabinoid production by neuronal depolarization and group I metabotropic glutamate receptor activation. Eur J Neurosci 2002, 15:953-961.
134. Ohno-Shosaku T., Tsubokawa H., Mizushima I., Yoneda N., Zimmer A., Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci 2002, 22:3864-3872.
135. Ong W.Y., Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience 1999, 92:1177-1191.
136. Oropeza V.C., Mackie K., Van Bockstaele E.J. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 2007, 1127:36-44.
137. Ortega-Alvaro A., Aracil-Fernández A., García-Gutiérrez M.S., Navarrete F., Manzanares J. Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 2011, 36:1489-1504.
138. Otani S., Auclair N., Desce J.M., Roisin M.P., Crépel F. Dopamine receptors and groups I and II mGluRs cooperate for long-term depression induction in rat prefrontal cortex through converging postsynaptic activation of MAP kinases. J Neurosci 1999, 19:9788-9802.
139. Otani S., Daniel H., Takita M., Crépel F. Long-term depression induced by postsynaptic group II metabotropic glutamate receptors linked to phospholipase C and intracellular calcium rises in rat prefrontal cortex. J Neurosci 2002, 22:3434-3444.
140. Pan B., Hillard C.J., Liu Q.S. D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling. J Neurosci 2008, 28:14018-14030.
141. Patel S., Rademacher D.J., Hillard C.J. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 2003, 306:880-888.
142. Perroy J., Raynaud F., Homburger V., Rousset M.C., Telley L., Bockaert J., et al. Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors. J Biol Chem 2008, 283:6799-6805.
143. Pistis M., Ferraro L., Pira L., Flore G., Tanganelli S., Gessa G.L., et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 2002, 948:155-158.
144. Polissidis A., Chouliara O., Galanopoulos A., Rentesi G., Dosi M., Hyphantis T., et al. Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol 2010, 13:1175-1191.
145. Poncelet M., Barnouin M.C., Breliere J.C., Le Fur G., Soubrie P. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berl) 1999, 144:144-150.
146. Pothos E., Rada P., Mark G.P., Hoebel B.G. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res 1991, 566:348-350.
147. Prohovnik I., Arnold S.E., Smith G., Lucas L.R. Physostigmine reversal of scopolamine-induced hypofrontality. J Cereb Blood Flow Metab 1997, 17:220-228.
148. Reibaud M., Obinu M.C., Ledent C., Parmentier M., Bohme G.A., Imperato A. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol 1999, 379:R1-R2.
149. Riegel A.C., Lupica C.R. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci 2004, 24:11070-11078.
150. Robbe D., Kopf M., Remaury A., Bockaert J., Manzoni O.J. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A 2002, 99:8384-8388.
151. Rodriguez De Fonseca F., Gorriti M.A., Bilbao A., Escuredo L., Garcia-Segura L.M., Piomelli D., et al. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox Res 2001, 3:23-35.
152. Rubino T., Patrini G., Massi P., Fuzio D., Vigano D., Giagnoni G., et al. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998, 285:813-819.
153. Santucci V., Storme J.J., Soubrié P., Le Fur G. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 1996, 58:PL103-10.
154. Sanudo-Pena M.C., Walker J.M. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 1997, 77:1635-1638.
155. Sanudo-Pena M.C., Romero J., Seale G.E., Fernandez-Ruiz J.J., Walker J.M. Activational role of cannabinoids on movement. Eur J Pharmacol 2000, 391:269-274.
156. Seillier A., Advani T., Cassano T., Hensler J.G., Giuffrida A. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol 2010, 13:373-386.
157. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
158. Sidhpura N., Parsons L.H. Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology 2011, 61:1070-1087.
159. Smith Y., Raju D.V., Pare J.F., Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci 2004, 27:520-527.
160. Solinas M., Panlilio L.V., Tanda G., Makriyannis A., Matthews S.A., Goldberg S.R. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 2005, 30:2046-2057.
161. Solinas M., Justinova Z., Goldberg S.R., Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 2006, 98:408-419.
162. Soria G., Mendizábal V., Touriño C., Robledo P., Ledent C., Parmentier M., et al. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 2005, 30:1670-1680.
163. Stefani A., Pisani A., Mercuri N.B., Calabresi P. The modulation of calcium currents by the activation of mGluRs. Functional implications. Mol Neurobiol 1996, 13:81-95.
164. Sulkova E., Mechoulam R., Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998, 59:347-352.
165. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Brain Res Rev 2000, 31:320-329.
166. Tanda G., Pontieri F.E., Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997, 276:2048-2050.
167. Tepper J.M., Lee C.R. GABAergic control of substantia nigra dopaminergic neurons. Prog Brain Res 2007, 160:189-208.
168. Terranova J.P., Storme J.J., Lafon N., Péio A., Rinaldi-Carmona M., Le Fur G., et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 1996, 126:165-172.
169. Terzian A.L., Drago F., Wotjak C.T., Micale V. The dopamine and cannabinoid interaction in the modulation of emotions and cognition: assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors. Front Behav Neurosci 2011, 5:49.
170. Toth A., Boczan J., Kedei N., Lizanecz E., Bagi Z., Papp Z., et al. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 2005, 135:162-168.
171. Tseng K.Y., O'Donnell P. Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci 2004, 24:5131-5139.
172. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
173. Tsou K., Mackie K., Sanudo-Pena M.C., Walker J.M. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 1999, 93:969-975.
174. Turkanis S.A., Karler R. Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat. Psychopharmacology (Berl) 1981, 75:294-298.
175. Tzavara E.T., Valjent E., Firmo C., Mas M., Beslot F., Defer N., et al. Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum. Eur J Neurosci 2000, 12:1038-1046.
176. Tzavara E.T., Monory K., Hanoune J., Nomikos G.G. Nicotine withdrawal syndrome: behavioural distress and selective up-regulation of the cyclic AMP pathway in the amygdala. Eur J Neurosci 2002, 16:149-153.
177. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003, 138:544-553.
178. Tzavara E.T., Wade M., Nomikos G.G. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 2003, 23:9374-9384.
179. Tzavara E.T., Bymaster F.P., Davis R.J., Wade M.R., Perry K.W., Wess J., et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 2004, 18:1410-1412.
180. Tzavara E.T., Li D.L., Moutsimilli L., Bisogno T., Di Marzo V., Phebus L.A., et al. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry 2006, 59:508-515.
181. Tzavara E.T., Wade M.R., Davis R.J., El Khoury M.A., Nomikos G.G. Role of metabotropic glutamate receptor 5 in the procholinergic effects of neuropsychotherapeutic compounds. Synapse 2008, 62:940-943.
182. Tzavara E.T., Degroot A., Wade M.R., Davis R.J., Nomikos G.G. CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors. Eur Neuropsychopharmacol 2009, 19:196-204.
183. Ueda N., Goparaju S.K., Katayama K., Kurahashi Y., Suzuki H., Yamamoto S. A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors. J Med Invest 1998, 45:27-36.
184. Varvel S.A., Lichtman A.H. Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 2002, 301:915-924.
185. Verrico C.D., Jentsch J.D., Roth R.H. Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 2003, 49:61-66.
186. Verrico C.D., Jentsch J.D., Roth R.H., Taylor J.R. Repeated, intermittent delta(9)-tetrahydrocannabinol administration to rats impairs acquisition and performance of a test of visuospatial divided attention. Neuropsychopharmacology 2004, 29:522-529.
187. Wallén-Mackenzie A., Nordenankar K., Fejgin K., Lagerström M.C., Emilsson L., Fredriksson R., et al. Restricted cortical and amygdaloid removal of vesicular glutamate transporter 2 in preadolescent mice impacts dopaminergic activity and neuronal circuitry of higher brain function. J Neurosci 2009, 29:2238-2251.
188. Wenger T., Moldrich G., Furst S. Neuromorphological background of cannabis addiction. Brain Res Bull 2003, 61:125-128.
189. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
190. Witkin J.M., Tzavara E.T., Nomikos G.G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 2005, 16:315-331.
191. Xi Z.X., Gilbert J.G., Peng X.Q., Pak A.C., Li X., Gardner E.L. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J Neurosci 2006, 26:8531-8536.
192. Yamamoto T., Anggadiredja K., Hiranita T. New perspectives in the studies on endocannabinoid and cannabis: a role for the endocannabinoid-arachidonic acid pathway in drug reward and long-lasting relapse to drug taking. J Pharmacol Sci 2004, 96(4):382-388. [Electronic publication 2004 Dec 10. Review.].
193. Yang C.R., Seamans J.K., Gorelova N. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 1999, 21:161-194.
194. Zhu P.J., Lovinger D.M. Persistent synaptic activity produces long-lasting enhancement of endocannabinoid modulation and alters long-term synaptic plasticity. J Neurophysiol 2007, 97:4386-4389.
195. Zuardi A.W., Morais S.L., Guimaraes F.S., Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995, 56:485-486.